The TREM2 gene provides instructions for making the TREM2 protein, which is found on the surface of myeloid cells . This protein interacts with the TYROBP gene product to mediate signal transduction, leading to various immune responses . Mutations in the TREM2 gene have been linked to several neurodegenerative diseases, including Alzheimer’s disease .
TREM2 is particularly significant in the context of neurodegenerative diseases. Homozygous mutations in TREM2 can cause early-onset progressive presenile dementia, while heterozygous point mutations increase the risk of Alzheimer’s disease . The receptor is involved in the clearance of amyloid-beta plaques, a hallmark of Alzheimer’s disease, by recruiting microglia to the plaques and enhancing their phagocytic activity .
Recent studies have explored the therapeutic potential of TREM2 activation. For instance, chronic activation of TREM2 in mouse models of amyloid deposition has shown promising results in reducing amyloid-beta levels and improving cognitive functions . These findings suggest that TREM2 activators could be effective in treating Alzheimer’s disease and possibly other neurodegenerative disorders .
In addition to its role in neurodegenerative diseases, TREM2 also plays a critical role in the host defense response to sepsis. It enhances bacterial clearance and improves survival rates in septic conditions . This receptor’s ability to regulate inflammatory responses and facilitate pathogen clearance makes it a potential target for therapeutic interventions in sepsis .